Should Investors Hold Chemed Stock in Their Portfolio Now?
CHE shows growth momentum from VITAS and resilient Roto-Rooter results, but macro headwinds and competition continue to cloud its near-term outlook.
Chemed (CHE) Upgraded to Buy: Here's What You Should Know
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chemtrade Logistics Income Fund (CHE.UN:CA) Q3 2025 Earnings Call Transcript
Chemtrade Logistics Income Fund ( CHE.UN:CA ) Q3 2025 Earnings Call November 12, 2025 10:00 AM EST Company Participants Rohit Bhardwaj - VP of Finance & CFO Scott Rook - CEO, President & Trustee Conference Call Participants Nikolai Goroupitch Joel Jackson - BMO Capital Markets Equity Research Ben Isaacson - Scotiabank Global Banking and Markets, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Chemtrade Logistics Income Fund Third Quarter 2025 Conference Call. [Operator Instructions] I would now like to turn the conference call over to Rohit Bhardwaj, Chief Financial Officer.
Chemed Corporation (CHE) Presents at UBS Global Healthcare Conference 2025 Transcript
Chemed Corporation ( CHE ) UBS Global Healthcare Conference 2025 November 11, 2025 2:00 PM EST Company Participants Michael Witzeman - Executive VP, Controller, Principal Accounting Officer & CFO Kevin McNamara - CEO, President & Director Joel Wherley - CEO, President & Chief Operating Officer Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Presentation Albert Rice UBS Investment Bank, Research Division All right. Thanks, everyone.
Wall Street Analysts Predict a 32.69% Upside in Chemed (CHE): Here's What You Should Know
The mean of analysts' price targets for Chemed (CHE) points to a 32.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Chemed Corporation (CHE) Q3 2025 Earnings Call Transcript
Chemed Corporation ( CHE ) Q3 2025 Earnings Call October 29, 2025 10:00 AM EDT Company Participants Holley Schmidt Kevin McNamara - CEO, President & Director Michael Witzeman - Executive VP, Controller, Principal Accounting Officer & CFO Joel Wherley - CEO, President & Chief Operating Officer Conference Call Participants Benjamin Hendrix - RBC Capital Markets, Research Division Brian Tanquilut - Jefferies LLC, Research Division Joanna Gajuk - BofA Securities, Research Division Presentation Operator Good morning, and thank you for standing by. Welcome to the Chemed Corporation Third Quarter 2025 Earnings Conference Call.
CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash
Chemed's Q3 miss sends shares lower as shrinking margins and weaker EPS overshadow steady revenue gains from VITAS and Roto-Rooter.
Chemed (CHE) Lags Q3 Earnings and Revenue Estimates
Chemed (CHE) came out with quarterly earnings of $5.27 per share, missing the Zacks Consensus Estimate of $5.39 per share. This compares to earnings of $5.64 per share a year ago.
Chemed Corporation (CHE) Q2 2025 Earnings Call Transcript
Chemed Corporation (NYSE:CHE ) Q2 2025 Earnings Conference Call July 30, 2025 10:00 AM ET Company Participants Holley Schmidt - Corporate Participant Kevin J. McNamara - CEO, President & Director Michael D.
Chemed (CHE) Q2 Earnings Miss Estimates
Chemed (CHE) came out with quarterly earnings of $4.27 per share, missing the Zacks Consensus Estimate of $4.78 per share. This compares to earnings of $5.47 per share a year ago.
Analysts Estimate Chemed (CHE) to Report a Decline in Earnings: What to Look Out for
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed Corporation: Short-Term Headwinds But Long-Term Growth Potential
Chemed Corporation's diversified revenue streams from VITAS Healthcare and Roto-Rooter provide a strong competitive advantage and resilience against sector-specific risks. Recent VITAS acquisition and expansion, along with robust Q1 results, highlight the company's growth potential and operational strength, especially in hospice care. My DCF analysis suggests Chemed is undervalued by over 50%, with a fair value estimate of $744 per share, supporting a buy rating.
